JP4399265B2 - 3,4−ジアリールピラゾール、および癌の治療におけるそれらの使用 - Google Patents
3,4−ジアリールピラゾール、および癌の治療におけるそれらの使用 Download PDFInfo
- Publication number
- JP4399265B2 JP4399265B2 JP2003556391A JP2003556391A JP4399265B2 JP 4399265 B2 JP4399265 B2 JP 4399265B2 JP 2003556391 A JP2003556391 A JP 2003556391A JP 2003556391 A JP2003556391 A JP 2003556391A JP 4399265 B2 JP4399265 B2 JP 4399265B2
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- arh
- compound
- group
- mmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 **(C=CC1)C=CC1c1n[n](*)c(*)c1* Chemical compound **(C=CC1)C=CC1c1n[n](*)c(*)c1* 0.000 description 13
- PDRQWICBTJDLOV-ATVHPVEESA-N C/C(/O)=C/C(c(c(OCc1ccccc1)c1)cc(Cl)c1OCc1ccccc1)=O Chemical compound C/C(/O)=C/C(c(c(OCc1ccccc1)c1)cc(Cl)c1OCc1ccccc1)=O PDRQWICBTJDLOV-ATVHPVEESA-N 0.000 description 1
- DFGUXDWFDXIKHB-XQRVVYSFSA-N C/C(/O)=C/C(c(cc(cc1)N)c1O)=O Chemical compound C/C(/O)=C/C(c(cc(cc1)N)c1O)=O DFGUXDWFDXIKHB-XQRVVYSFSA-N 0.000 description 1
- DXKBHBTVHZCDSV-UHFFFAOYSA-N CC(CC=C1OCc2ccccc2)(C=C1Cl)c1n[nH]c(C)c1 Chemical compound CC(CC=C1OCc2ccccc2)(C=C1Cl)c1n[nH]c(C)c1 DXKBHBTVHZCDSV-UHFFFAOYSA-N 0.000 description 1
- QCTGWCJUKBFYQK-UHFFFAOYSA-N CC(Oc(c1c2)cc(O)c2Cl)=C(c(cc2)ccc2OCCCC#N)C1=O Chemical compound CC(Oc(c1c2)cc(O)c2Cl)=C(c(cc2)ccc2OCCCC#N)C1=O QCTGWCJUKBFYQK-UHFFFAOYSA-N 0.000 description 1
- DRLASCMXLWGTNW-UHFFFAOYSA-N CC1(C=CC(c2c(C)[nH]nc2-c(c(O)c2)cc(Cl)c2O)=CC=C1)c1cccnc1 Chemical compound CC1(C=CC(c2c(C)[nH]nc2-c(c(O)c2)cc(Cl)c2O)=CC=C1)c1cccnc1 DRLASCMXLWGTNW-UHFFFAOYSA-N 0.000 description 1
- JGHPPNLZKDOBQX-UHFFFAOYSA-N CC1C(CC2)C2CC1 Chemical compound CC1C(CC2)C2CC1 JGHPPNLZKDOBQX-UHFFFAOYSA-N 0.000 description 1
- RUQMHVYPVLGJJE-VJZJJAJZSA-N CCOC(/C(/C=C(\C)/c1n[nH]c(C)c1-c(cc1)cc2c1OCCO2)=C/C)=O Chemical compound CCOC(/C(/C=C(\C)/c1n[nH]c(C)c1-c(cc1)cc2c1OCCO2)=C/C)=O RUQMHVYPVLGJJE-VJZJJAJZSA-N 0.000 description 1
- UPVFKXADRBQUPF-UHFFFAOYSA-N CCc(c(O)c1)cc(-c2n[nH]cc2-c2ccccc2)c1O Chemical compound CCc(c(O)c1)cc(-c2n[nH]cc2-c2ccccc2)c1O UPVFKXADRBQUPF-UHFFFAOYSA-N 0.000 description 1
- BUMSQLSMWAQABP-UHFFFAOYSA-N CCc(cc(c(OC=C1c2ccccc2)c2)C1=O)c2O Chemical compound CCc(cc(c(OC=C1c2ccccc2)c2)C1=O)c2O BUMSQLSMWAQABP-UHFFFAOYSA-N 0.000 description 1
- LFIHCWCVFFOMNV-UHFFFAOYSA-N COc(c(OC)c1)ccc1C(C(c1c2)=O)=COc1cc(O)c2Cl Chemical compound COc(c(OC)c1)ccc1C(C(c1c2)=O)=COc1cc(O)c2Cl LFIHCWCVFFOMNV-UHFFFAOYSA-N 0.000 description 1
- ARODJBIRINXCJI-UHFFFAOYSA-N COc(cc1)ccc1-c(c(-c(cc(c(O)c1)Cl)c1O)n[nH]1)c1Br Chemical compound COc(cc1)ccc1-c(c(-c(cc(c(O)c1)Cl)c1O)n[nH]1)c1Br ARODJBIRINXCJI-UHFFFAOYSA-N 0.000 description 1
- GATNWQWCPMFSTP-UHFFFAOYSA-N Cc([nH]nc1-c(cc2Cl)ccc2OCc2ccccc2)c1I Chemical compound Cc([nH]nc1-c(cc2Cl)ccc2OCc2ccccc2)c1I GATNWQWCPMFSTP-UHFFFAOYSA-N 0.000 description 1
- YCWNYOBKZBQZKF-UHFFFAOYSA-N Cc([nH]nc1-c(ccc(O)c2C)c2O)c1-c(cc1)ccc1OC Chemical compound Cc([nH]nc1-c(ccc(O)c2C)c2O)c1-c(cc1)ccc1OC YCWNYOBKZBQZKF-UHFFFAOYSA-N 0.000 description 1
- QRQAPTPQGGJNBS-UHFFFAOYSA-N Cc(cc1)ccc1C(C(c1c2)=O)=C(C)Oc1cc(O)c2Cl Chemical compound Cc(cc1)ccc1C(C(c1c2)=O)=C(C)Oc1cc(O)c2Cl QRQAPTPQGGJNBS-UHFFFAOYSA-N 0.000 description 1
- ABXPOGMEVBZRHJ-UHFFFAOYSA-N Cc1cc(-c(cc2)ccc2S(N)(=O)=O)n[nH]1 Chemical compound Cc1cc(-c(cc2)ccc2S(N)(=O)=O)n[nH]1 ABXPOGMEVBZRHJ-UHFFFAOYSA-N 0.000 description 1
- CUKMYJWVRPBKQT-UHFFFAOYSA-N Cc1ccccc1C(C(c1c2)=O)=C(C)Oc1cc(O)c2Cl Chemical compound Cc1ccccc1C(C(c1c2)=O)=C(C)Oc1cc(O)c2Cl CUKMYJWVRPBKQT-UHFFFAOYSA-N 0.000 description 1
- RLYUNPNLXMSXAX-UHFFFAOYSA-N Cc1cnc[s]1 Chemical compound Cc1cnc[s]1 RLYUNPNLXMSXAX-UHFFFAOYSA-N 0.000 description 1
- DXYYSGDWQCSKKO-UHFFFAOYSA-N Cc1nc(cccc2)c2[s]1 Chemical compound Cc1nc(cccc2)c2[s]1 DXYYSGDWQCSKKO-UHFFFAOYSA-N 0.000 description 1
- XZGLNCKSNVGDNX-UHFFFAOYSA-N Cc1nnn[nH]1 Chemical compound Cc1nnn[nH]1 XZGLNCKSNVGDNX-UHFFFAOYSA-N 0.000 description 1
- WMNHFQHLGLRCRL-UHFFFAOYSA-N Clc(c(OCc1ccccc1)c1)cc(-c2n[nH]cc2I)c1OCc1ccccc1 Chemical compound Clc(c(OCc1ccccc1)c1)cc(-c2n[nH]cc2I)c1OCc1ccccc1 WMNHFQHLGLRCRL-UHFFFAOYSA-N 0.000 description 1
- DHSYPRCKNJUZOC-UHFFFAOYSA-N Oc(cc(c(Cl)c1)O)c1-c1n[nH]cc1-c1cc(OCCF)ccc1 Chemical compound Oc(cc(c(Cl)c1)O)c1-c1n[nH]cc1-c1cc(OCCF)ccc1 DHSYPRCKNJUZOC-UHFFFAOYSA-N 0.000 description 1
- ZXCUPVSTUUVJNT-UHFFFAOYSA-N Oc(cc(c(Cl)c1)O)c1C(Cc1ccccc1Br)=O Chemical compound Oc(cc(c(Cl)c1)O)c1C(Cc1ccccc1Br)=O ZXCUPVSTUUVJNT-UHFFFAOYSA-N 0.000 description 1
- SKMRQICJTLTLTF-UHFFFAOYSA-N Oc(cc1)cc(O)c1-c1n[nH]cc1-c(cc1)ccc1Br Chemical compound Oc(cc1)cc(O)c1-c1n[nH]cc1-c(cc1)ccc1Br SKMRQICJTLTLTF-UHFFFAOYSA-N 0.000 description 1
- AKEFWJSSHVZSBL-UHFFFAOYSA-N Oc1cc(O)ccc1-c1n[nH]cc1-c1ccccc1 Chemical compound Oc1cc(O)ccc1-c1n[nH]cc1-c1ccccc1 AKEFWJSSHVZSBL-UHFFFAOYSA-N 0.000 description 1
- XBLKRYDMZYKNFI-UHFFFAOYSA-N Sc1ccc2OCCCOc2c1 Chemical compound Sc1ccc2OCCCOc2c1 XBLKRYDMZYKNFI-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/16—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0130733A GB0130733D0 (en) | 2001-12-21 | 2001-12-21 | Therapeutic compounds and their use in therapy |
| GB0225688A GB0225688D0 (en) | 2002-11-04 | 2002-11-04 | Therapeutic compounds and their use in therapy |
| PCT/GB2002/005778 WO2003055860A1 (en) | 2001-12-21 | 2002-12-19 | 3,4-diarylpyrazoles and their use in the therapy of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005517675A JP2005517675A (ja) | 2005-06-16 |
| JP2005517675A5 JP2005517675A5 (cg-RX-API-DMAC7.html) | 2006-02-09 |
| JP4399265B2 true JP4399265B2 (ja) | 2010-01-13 |
Family
ID=26246898
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003556391A Expired - Fee Related JP4399265B2 (ja) | 2001-12-21 | 2002-12-19 | 3,4−ジアリールピラゾール、および癌の治療におけるそれらの使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7247734B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1456180B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP4399265B2 (cg-RX-API-DMAC7.html) |
| AT (1) | ATE374753T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2002356301A1 (cg-RX-API-DMAC7.html) |
| DE (1) | DE60222804T2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2003055860A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (104)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005519878A (ja) | 2001-11-30 | 2005-07-07 | キネテク ファーマシューティカルズ,インコーポレーテッド | ヒドラゾノピラゾール誘導体および治療剤としてのその使用 |
| US6770597B2 (en) * | 2002-07-17 | 2004-08-03 | Ishihara Sangyo Kaisha, Ltd. | Benzohydrazide derivatives as herbicides and desiccant compositions containing them |
| EP1542997B1 (en) * | 2002-07-24 | 2012-02-29 | Dermira (Canada), Inc. | Pyrazolylbenzothiazole derivatives and their use as therapeutic agents |
| ATE323702T1 (de) | 2002-08-06 | 2006-05-15 | Astrazeneca Ab | Kondensierte pyridine und pyrimidine mit tie2 (tek) aktivität |
| US7468445B2 (en) | 2002-08-07 | 2008-12-23 | University Of Mississippi | Antigiardial agents and use thereof |
| GB0228417D0 (en) | 2002-12-05 | 2003-01-08 | Cancer Rec Tech Ltd | Pyrazole compounds |
| GB0229618D0 (en) * | 2002-12-19 | 2003-01-22 | Cancer Rec Tech Ltd | Pyrazole compounds |
| KR101166749B1 (ko) * | 2003-02-11 | 2012-07-27 | 베르날리스(캠브리지)리미티드 | 열쇼크 단백질 저해제로서의 이소옥사졸 화합물 |
| CA2520804A1 (en) | 2003-04-03 | 2004-10-28 | Merck & Co., Inc. | Biaryl substituted pyrazoles as sodium channel blockers |
| GB0309637D0 (en) * | 2003-04-28 | 2003-06-04 | Cancer Rec Tech Ltd | Pyrazole compounds |
| GB0313915D0 (en) * | 2003-06-16 | 2003-07-23 | Smithkline Beecham Corp | Compounds |
| EP1704856A4 (en) * | 2003-12-26 | 2009-08-19 | Kyowa Hakko Kirin Co Ltd | PROTEIN INHIBITOR OF THE HSP90 FAMILY |
| CA2551948A1 (en) * | 2004-01-09 | 2005-07-28 | Novartis Ag | Phenyl-[4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yl]-amine derivatives as igf-ir inhibitors |
| GB0402518D0 (en) | 2004-02-05 | 2004-03-10 | Astrazeneca Ab | Therapeutic agents |
| WO2005110963A1 (en) * | 2004-05-19 | 2005-11-24 | Cellzome Ag | (biphenyl-3-yl)-carboxylic acids and derivatives thereof and their use in therapy |
| EP1604970A1 (en) * | 2004-05-19 | 2005-12-14 | Cellzome Ag | 2-(Biphenyl-3-yl)-carboxylic acids of gamma-secretase-modulating activity |
| DE102004039280A1 (de) * | 2004-08-13 | 2006-02-23 | Merck Patent Gmbh | 1,5-Diphenyl-pyrazole |
| CN101023119B (zh) | 2004-09-22 | 2010-05-05 | 日本化药株式会社 | 新型嵌段共聚物,胶束制剂以及含胶束制剂为活性组分的抗癌剂 |
| DE102004049078A1 (de) | 2004-10-08 | 2006-04-13 | Merck Patent Gmbh | Phenylpyrazole |
| ES2594874T3 (es) | 2004-11-18 | 2016-12-23 | Synta Pharmaceuticals Corp. | Compuestos de triazol que modulan la actividad de HSP90 |
| TW200639163A (en) | 2005-02-04 | 2006-11-16 | Genentech Inc | RAF inhibitor compounds and methods |
| DE102005007304A1 (de) | 2005-02-17 | 2006-08-24 | Merck Patent Gmbh | Triazolderivate |
| JPWO2006088193A1 (ja) * | 2005-02-21 | 2008-07-03 | 協和醗酵工業株式会社 | 抗腫瘍剤 |
| DE102005009440A1 (de) | 2005-03-02 | 2006-09-07 | Merck Patent Gmbh | Thienopyridinderivate |
| EP1857446B1 (en) | 2005-03-09 | 2013-05-01 | Nippon Kayaku Kabushiki Kaisha | Derivatives of 3-(2,4-dihydroxyphenyl)-1,2,4-triazole useful in the treatment of cancer |
| CN101193862B (zh) | 2005-04-13 | 2013-08-21 | 阿斯特克斯治疗有限公司 | 羟基苯甲酰胺衍生物和其作为hsp90抑制剂的用途 |
| WO2006122546A1 (de) * | 2005-05-18 | 2006-11-23 | Forschungsverbund Berlin E.V. | Nicht-peptidische inhibitoren der akap-pka-wechselwirkung |
| FR2885904B1 (fr) * | 2005-05-19 | 2007-07-06 | Aventis Pharma Sa | Nouveaux derives du fluorene, compositions les contenant et utilisation |
| US7473784B2 (en) * | 2005-08-01 | 2009-01-06 | Bristol-Myers Squibb Company | Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors |
| WO2007021966A1 (en) * | 2005-08-12 | 2007-02-22 | Synta Pharmaceuticals Corp. | Pyrazole compounds that modulate hsp90 activity |
| CA2618628C (en) | 2005-08-18 | 2014-11-18 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
| NL2000351C2 (nl) | 2005-12-22 | 2007-09-11 | Pfizer Prod Inc | Estrogeen-modulatoren. |
| US20070253896A1 (en) * | 2006-02-07 | 2007-11-01 | Conforma Therapeutics Corporation | 7,9-Dihydro-Purin-8-One and Related Analogs as HSP90-Inhibitors |
| US7754725B2 (en) | 2006-03-01 | 2010-07-13 | Astex Therapeutics Ltd. | Dihydroxyphenyl isoindolymethanones |
| CA2643066A1 (en) * | 2006-03-16 | 2007-09-20 | Pfizer Products Inc. | Pyrazole compounds |
| KR20080106254A (ko) | 2006-03-28 | 2008-12-04 | 니폰 가야꾸 가부시끼가이샤 | 탁산류의 고분자 결합체 |
| CA2652656A1 (en) | 2006-05-18 | 2007-11-29 | Nippon Kayaku Kabushiki Kaisha | High-molecular weight conjugate of podophyllotoxins |
| DE102006023336A1 (de) | 2006-05-18 | 2007-11-22 | Merck Patent Gmbh | 1,5-Diphenyl-pyrazole II |
| JP5441691B2 (ja) | 2006-05-25 | 2014-03-12 | シンタ ファーマシューティカルズ コーポレーション | Hsp90活性を調節するトリアゾール化合物 |
| AU2007267803B2 (en) * | 2006-05-25 | 2011-08-25 | Synta Pharmaceuticals Corp. | Method for treating non-Hodgkin's lymphoma |
| US8034834B2 (en) | 2006-05-25 | 2011-10-11 | Synta Pharmaceuticals Corp. | Method for treating proliferative disorders with HSP90 inhibitors |
| AR061185A1 (es) | 2006-05-26 | 2008-08-13 | Chugai Pharmaceutical Co Ltd | Compuestos heterociclicos como inhibidores de hsp90. composiciones farmaceuticas. |
| CA2664852A1 (en) * | 2006-10-03 | 2008-04-10 | Nippon Kayaku Kabushiki Kaisha | High-molecular weight conjugate of resorcinol derivatives |
| US8916552B2 (en) | 2006-10-12 | 2014-12-23 | Astex Therapeutics Limited | Pharmaceutical combinations |
| JP5518478B2 (ja) | 2006-10-12 | 2014-06-11 | アステックス、セラピューティックス、リミテッド | 医薬化合物 |
| GB0620259D0 (en) | 2006-10-12 | 2006-11-22 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| US8883790B2 (en) | 2006-10-12 | 2014-11-11 | Astex Therapeutics Limited | Pharmaceutical combinations |
| JP5410285B2 (ja) | 2006-10-12 | 2014-02-05 | アステックス、セラピューティックス、リミテッド | 医薬化合物 |
| JP5721949B2 (ja) | 2006-10-12 | 2015-05-20 | アステックス、セラピューティックス、リミテッドAstex Therapeutics Limited | 複合薬剤 |
| EP2080779B1 (en) | 2006-11-06 | 2016-05-18 | Nippon Kayaku Kabushiki Kaisha | Polymeric derivative of nucleic acid metabolic antagonist |
| EP2090607B1 (en) | 2006-11-08 | 2015-05-20 | Nippon Kayaku Kabushiki Kaisha | Polymeric derivative of nucleic acid metabolic antagonist |
| DE102007002715A1 (de) | 2007-01-18 | 2008-07-24 | Merck Patent Gmbh | Triazolderivat |
| PE20090110A1 (es) | 2007-03-01 | 2009-04-04 | Chugai Pharmaceutical Co Ltd | Compuestos macrociclicos derivados de amina como agentes inhibidores de hsp90 |
| TW200901960A (en) | 2007-03-05 | 2009-01-16 | Kyowa Hakko Kogyo Kk | Pharmaceutical composition |
| US8993608B2 (en) | 2007-03-12 | 2015-03-31 | Synta Pharmaceuticals Corp. | Method for inhibiting topoisomerase II |
| BRPI0815042A2 (pt) * | 2007-08-01 | 2015-02-10 | Pfizer | Compostos de pirazol |
| WO2009026658A1 (en) * | 2007-08-29 | 2009-03-05 | The University Of Sydney | Ppar agonists |
| CA2699794C (en) | 2007-09-10 | 2016-07-19 | University Of Massachusetts | Mitochondria-targeted anti-tumor agents |
| US8703878B2 (en) | 2007-09-28 | 2014-04-22 | Nippon Kayaku Kabushiki Kaisha | High-molecular weight conjugate of steroids |
| KR101589582B1 (ko) | 2008-03-18 | 2016-01-28 | 니폰 가야꾸 가부시끼가이샤 | 생리활성물질의 고분자량 결합체 |
| GB0806527D0 (en) | 2008-04-11 | 2008-05-14 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| JP5366940B2 (ja) | 2008-05-08 | 2013-12-11 | 日本化薬株式会社 | 葉酸若しくは葉酸誘導体の高分子結合体 |
| WO2010001989A1 (ja) * | 2008-07-03 | 2010-01-07 | 協和発酵キリン株式会社 | 癌幹細胞及び/または癌前駆細胞の減少剤並びに癌の再発及び/または転移の予防剤 |
| EP2324008B1 (en) | 2008-07-24 | 2012-05-09 | Nerviano Medical Sciences S.R.L. | 3,4-diarylpyrazoles as protein kinase inhibitors |
| EP2151434A1 (en) | 2008-08-05 | 2010-02-10 | Institut Pasteur | Alkoxypyrazoles and the process for their preparation |
| EP2151433A1 (en) | 2008-08-05 | 2010-02-10 | Institut Pasteur | Alkoxypyrazoles and the process for their preparation |
| PL2406216T3 (pl) * | 2009-03-11 | 2017-09-29 | Bayer Intellectual Property Gmbh | Ketoenole podstawione halogenoalkilometylenoksyfenylem |
| CN102438988B (zh) | 2009-04-21 | 2015-06-24 | 内尔维阿诺医学科学有限公司 | 作为hsp90抑制剂的间苯二酚衍生物 |
| JP5544357B2 (ja) | 2009-05-15 | 2014-07-09 | 日本化薬株式会社 | 水酸基を有する生理活性物質の高分子結合体 |
| NZ623069A (en) | 2009-08-17 | 2015-11-27 | Sloan Kettering Inst Cancer | Heat shock protein binding compounds, compositions, and methods for making and using same |
| JO3002B1 (ar) | 2009-08-28 | 2016-09-05 | Irm Llc | مركبات و تركيبات كمثبطات كيناز بروتين |
| WO2011040421A1 (ja) | 2009-09-29 | 2011-04-07 | 武田薬品工業株式会社 | スクリーニング方法 |
| AR078538A1 (es) | 2009-10-07 | 2011-11-16 | Karobio Ab | Pirroles e imidazoles sustituidos como ligandos del receptor de estrogenos |
| AU2011209234B2 (en) * | 2010-01-27 | 2015-05-07 | Nerviano Medical Sciences S.R.L. | Sulfonamido derivatives of 3,4-diarylpyrazoles as protein kinase inhibitors |
| CN102753546A (zh) * | 2010-02-17 | 2012-10-24 | 日东制药株式会社 | 新型5-元杂环衍生物及其制备方法 |
| US9205086B2 (en) | 2010-04-19 | 2015-12-08 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor |
| JP5938038B2 (ja) | 2010-08-03 | 2016-06-22 | ネルヴィアーノ・メディカル・サイエンシズ・ソチエタ・ア・レスポンサビリタ・リミタータ | ピラゾロフェニル−ベンゼンスルホンアミド化合物の誘導体及びその抗腫瘍薬としての使用 |
| JP5856069B2 (ja) | 2010-11-17 | 2016-02-09 | 日本化薬株式会社 | 新規なシチジン系代謝拮抗剤の高分子誘導体 |
| GB201113538D0 (en) | 2011-08-04 | 2011-09-21 | Karobio Ab | Novel estrogen receptor ligands |
| JP5711378B2 (ja) | 2011-09-11 | 2015-04-30 | 日本化薬株式会社 | ブロック共重合体の製造方法 |
| WO2013067162A1 (en) | 2011-11-02 | 2013-05-10 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors |
| AU2012332424A1 (en) | 2011-11-02 | 2014-06-05 | Synta Pharmaceuticals Corp. | Combination therapy of Hsp90 inhibitors with platinum-containing agents |
| JP6150813B2 (ja) | 2011-11-11 | 2017-06-21 | ノバルティス アーゲー | 増殖性疾患の治療方法 |
| WO2013074594A1 (en) | 2011-11-14 | 2013-05-23 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitors with braf inhibitors |
| CA2856406C (en) | 2011-11-23 | 2020-06-23 | Novartis Ag | Pharmaceutical formulations |
| CN103183640B (zh) * | 2011-12-30 | 2016-04-27 | 沈阳药科大学 | 二芳基吡唑类化合物及其制备方法与用途 |
| US20140079636A1 (en) * | 2012-04-16 | 2014-03-20 | Dinesh U. Chimmanamada | Targeted therapeutics |
| DE102013012685A1 (de) * | 2013-07-31 | 2015-02-05 | Johann-Wolfgang-Goethe Universität Frankfurt am Main | Arylierte Pyrazolderivate und deren Verwendung als Fluoreszenzfarbstoffe |
| CN104974091B (zh) * | 2014-04-10 | 2018-01-02 | 沈阳药科大学 | 3‑甲基‑1,5‑二芳基吡唑类化合物及其制备方法和用途 |
| EA201692155A1 (ru) | 2014-05-13 | 2017-04-28 | Мемориал Слоун-Кеттеринг Кэнсэ Сентр | МОДУЛЯТОРЫ Hsp70 И СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ |
| FR3022244B1 (fr) * | 2014-06-17 | 2016-07-01 | Centre Nat De La Rech Scient (Cnrs) | Utilisation d'un nouveau compose 3-aryl-4-catechol-pyrrole-n-propanol et ses derives pour le traitement du cancer et des pathologies associees a une angiogenese excessive |
| JP6760946B2 (ja) * | 2015-01-22 | 2020-09-23 | チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッドChia Tai Tianqing Pharmaceutical Group Co., Ltd. | Hsp90阻害剤としてのレゾルシノール誘導体 |
| GB201706806D0 (en) | 2017-04-28 | 2017-06-14 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| US11377447B2 (en) | 2017-06-20 | 2022-07-05 | Madrigal Pharmaceuticals, Inc. | Targeted therapeutics |
| US11491145B2 (en) | 2017-06-20 | 2022-11-08 | Madrigal Pharmaceuticals, Inc. | Combination therapies comprising targeted therapeutics |
| WO2019236765A1 (en) * | 2018-06-05 | 2019-12-12 | Flagship Pioneering Innovations V, Inc. | Acylated catechin polyphenols and methods of their use for the treatment of cancer |
| CN109134204B (zh) * | 2018-11-16 | 2022-03-08 | 棓诺(苏州)新材料有限公司 | 中间体2-溴-4-氟-5-氯苯酚的合成法 |
| CN110283080A (zh) * | 2019-07-05 | 2019-09-27 | 山西大学 | 一种含氟的二苯甲酮衍生物及其制备方法和应用 |
| EP3827825A1 (en) * | 2019-11-26 | 2021-06-02 | Wageningen Universiteit | Use of 3, 4-diarylpyrazoles as antibacterial agents |
| US20230348454A1 (en) * | 2020-09-14 | 2023-11-02 | Genzyme Corporation | Compounds as modulators of bis-phosphoglycerate mutase for the treatment of sickle cell disease |
| GB202015187D0 (en) | 2020-09-25 | 2020-11-11 | Sentinel Oncology Ltd | A pharmaceutical salt |
| WO2022232259A1 (en) * | 2021-04-28 | 2022-11-03 | Cornell University | Soluble adenylyl cyclase (sac) inhibitors and uses thereof |
| WO2023004280A1 (en) * | 2021-07-19 | 2023-01-26 | The Board Of Trustees Of The Leland Stanford Junior University | Selective pyrazole lrrk2 inhibitors and methods for use thereof |
| CN120623147B (zh) * | 2025-08-01 | 2025-12-16 | 广东省科学院动物研究所 | 吡唑喹啉醚类化合物及其在制备神经保护药物中的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5559137A (en) * | 1994-05-16 | 1996-09-24 | Smithkline Beecham Corp. | Compounds |
| US5486534A (en) * | 1994-07-21 | 1996-01-23 | G. D. Searle & Co. | 3,4-substituted pyrazoles for the treatment of inflammation |
| US5932576A (en) * | 1997-05-22 | 1999-08-03 | G. D. Searle & Company | 3(5)-heteroaryl substituted pyrazoles as p38 kinase inhibitors |
| DE69935335T2 (de) * | 1998-08-07 | 2007-11-22 | Novartis Vaccines and Diagnostics, Inc., Emeryville | Pyrazole als modulatoren des östrogenrezeptors |
| AU1199600A (en) | 1998-10-02 | 2000-04-26 | Board Of Trustees Of The University Of Illinois, The | Estrogen receptor ligands |
| ATE291020T1 (de) | 2001-02-02 | 2005-04-15 | Smithkline Beecham Corp | Pyrazolderivate gegen tgf überexprimierung |
| GB0102687D0 (en) * | 2001-02-02 | 2001-03-21 | Pharmacia & Upjohn Spa | Oxazolyl-pyrazole derivatives active as kinase inhibitors,process for their preparation and pharmaceutical compositions comprising them |
| JP2005022972A (ja) * | 2001-05-16 | 2005-01-27 | Teikoku Hormone Mfg Co Ltd | 4−(4−ピリダジニル)ピラゾール誘導体 |
-
2002
- 2002-12-19 JP JP2003556391A patent/JP4399265B2/ja not_active Expired - Fee Related
- 2002-12-19 US US10/499,030 patent/US7247734B2/en not_active Expired - Fee Related
- 2002-12-19 AU AU2002356301A patent/AU2002356301A1/en not_active Abandoned
- 2002-12-19 DE DE60222804T patent/DE60222804T2/de not_active Expired - Lifetime
- 2002-12-19 EP EP02805823A patent/EP1456180B1/en not_active Expired - Lifetime
- 2002-12-19 AT AT02805823T patent/ATE374753T1/de not_active IP Right Cessation
- 2002-12-19 WO PCT/GB2002/005778 patent/WO2003055860A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| AU2002356301A1 (en) | 2003-07-15 |
| WO2003055860A1 (en) | 2003-07-10 |
| ATE374753T1 (de) | 2007-10-15 |
| DE60222804D1 (de) | 2007-11-15 |
| JP2005517675A (ja) | 2005-06-16 |
| US20050222230A1 (en) | 2005-10-06 |
| DE60222804T2 (de) | 2008-07-03 |
| US7247734B2 (en) | 2007-07-24 |
| EP1456180A1 (en) | 2004-09-15 |
| EP1456180B1 (en) | 2007-10-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005517675A (ja) | 3,4−ジアリールピラゾール、および癌の治療におけるそれらの使用 | |
| US10941152B2 (en) | Pyrazole compounds as modulators of FSHR and uses thereof | |
| US6291505B1 (en) | Estrogen receptor modulators | |
| JP4575779B2 (ja) | 癌治療用のhsp90阻害剤としての3−(2−ヒドロキシ−フェニル)−1h−ピラゾール−4−カルボン酸アミド誘導体 | |
| TW202210488A (zh) | 吡嗪類衍生物及其在抑制shp2中的應用 | |
| CN107231802B (zh) | 杂环衍生物及其用途 | |
| JP4921162B2 (ja) | 熱ショックタンパク質の阻害剤としてのイソオキサゾール化合物類 | |
| AU2003217393B2 (en) | Ansamycins having improved pharmacological and biological properties | |
| JP4528131B2 (ja) | ピラゾール化合物 | |
| AU2001260504A1 (en) | Barbituric acid analogs as therapeutic agents | |
| EA017852B1 (ru) | Производные замещенных индазолов, активные в качестве ингибиторов киназ | |
| EP1065203A2 (en) | Heterocyclic compounds as retinoic acid receptor antagonists | |
| US20210009581A1 (en) | Ion channel inhibitor compounds for cancer treatment | |
| WO2007029021A1 (en) | 1,5-substituted tetrazoles as therapeutic compounds | |
| JP2019532929A (ja) | 化合物およびpde4活性剤としてのそれらの使用 | |
| Özdemir et al. | Evaluation of cytotoxic activity of new benzimidazole-piperazine hybrids against human MCF-7 and A549 cancer cells | |
| KR20250068738A (ko) | 치환된 옥소이소인돌리닐 피페리딘-2,6-디온 화합물 | |
| KR20070045290A (ko) | Hsp90의 억제제 | |
| US20210024499A1 (en) | Oxidized bis(3-indolyl)methanes and uses thereof | |
| EP1416936B1 (en) | Thiopyrane-4-ones as dna protein kinase inhibitors | |
| USRE39708E1 (en) | Estrogen receptor modulators | |
| CA3099847A1 (en) | Mitogen-activated protein kinase kinase 7 inhibitors | |
| JPH05112571A (ja) | ピリミジン誘導体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20051212 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20051212 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090609 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20090610 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090907 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20091006 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20091026 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121030 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |